Background: Severe, intractable pruritus is a debilitating symptom in approximately 40% of SSc cases. It has been particularly associated with severe diffuse skin disease and resolution often coincides with clinical improvement in cutaneous sclerosis. Resistance of itch to treatment with classical anti-histamine based-therapy makes it especially challenging. The pathophysiology of itch is complex, involving several immuno-neurological factors. One novel cytokine, IL-31, produced by dermal mast cells and most notably, differentiated activated CD4 þ T helper 2 cells, has been implicated in mediating allergy and atopy. Studies have demonstrated elevated serum IL-31 and upregulated IL-31 mRNA, in patients with severe itch due to chronic dermopathies such as atopic eczema, allergic contact dermatitis and nodular prurigo. In some cases, IL-31 levels correlated with disease activity. Studies of transgenic mice have suggested IL-31 induces severe pruritus and serum levels correlate with scratching behaviour. In this study, we explore the role of IL-31 in the pathophysiology of itch in patients with SSc and consider the cytokine a novel target for therapeutic modulation. Methods: IL-31 levels in dermal blister-fluid and serum samples were measured using ELISAs in a cohort of SSc cases and healthy controls. SSc cases with pruritus were asked to complete the standardized 5D-Pruritus questionnaire to enable quantitative analysis of itch severity. RT-PCR was employed to determine IL-31 and IL-31 receptor expression, using messenger RNA extracted from dermal keratinocytes. Flow cytometry will be performed to analyse intracellular IL-31 expression and clinical correlation will be undertaken, to evaluate the relationship between itch severity, disease characteristics and IL-31 levels. Results: IL-31 expression was significantly increased in the dermal blister-fluid of some of the 26 SSc cases, with a mean IL-31 concentration 125.7 pg/ml vs 2.3 pg/ml in the 15 healthy controls (Z ¼ -2.54, P ¼ 0.006). Subgroup analysis revealed that the 12 limited cutaneous SSc cases in this study had a mean interstitial fluid IL-31 of 80.1 pg/ml, compared with a mean of 164.8 pg/ml in the 14 diffuse cases (P > 0.05). In addition, 90 serum samples were analysed for IL-31 concentration; a mean of 196 pg/ml was found in the 27 healthy controls, compared with 1914 pg/ml in the 63 SSc patient samples, with a trend to statistical significance (Z ¼ À1.64, P ¼ 0.05). Preliminary data havw demonstrated a 3.7-fold increase in IL-31 receptor gene expression between SSc and control RNA. Conclusion: Together, these results suggest that IL-31 may be increased in SSc and that this difference is especially seen in dermal interstitial fluid. This makes IL-31 a key candidate mediator for the intractable itch that may be a hallmark of active SSc skin disease and may represent a novel therapeutic target. Furthermore, the IL-31 axis may play a role in other aspects of the pathophysiology of SSc; thus, further evaluation is warranted. 
